Tuesday, 23 April 2024
Tuesday, 23 April 2024

Charity thanks NHS patients and staff for helping vital genetic research

NATIONAL charity Sepsis Research FEAT is marking Clinical Trials Day today by thanking NHS patients and staff for the part they have played in collecting over 12,000 samples as part of a ground-breaking research study.

The study at the world-leading Roslin Institute into the genetics of susceptibility and mortality in critical care (GenOMICC), which the charity has helped to fund for three years, researches how our genes can influence the body’s response to conditions such as COVID and sepsis.

Sepsis Research FEAT is paying tribute to patients in intensive care units and their families who allowed their DNA samples to be collected for the GenOMICC study and to the NHS staff who took the samples. These important samples offered early data to scientists searching for treatments for COVID. The GenOMICC team identified five genes that, when faulty, lead the body’s immune response to go into overdrive, putting patients at risk of damaging lung inflammation, potential systemic organ failure and ultimately death.

When the coronavirus pandemic struck, the GenOMICC study had already been gathering DNA samples from sepsis patients in intensive care units throughout the UK. Because there are similarities between sepsis and COVID, the work being carried out at the Roslin Institute was re-purposed to help in the fight against the pandemic.

Working with Oxford University and Genomics England facilitated a rise in the number of gene samples available to the Roslin Institute. On the anniversary of the first UK lockdown in March this year, the numbers of DNA samples collected from patients stood at 12,000 – some 11,000 higher than the same time the previous year.

Colin Graham, Chief Operating Officer at Sepsis Research FEAT, said:

“On behalf of everyone at Sepsis Research FEAT, I would like to offer my immense thanks to NHS staff, patients, and their families for helping this important research through the DNA samples gathered. Not only have these samples provided crucial data that has helped scientists in the fight against COVID, but they will also play an important part in the fight against sepsis.

“Sepsis is a life-threatening illness and kills around 50,000 people in the UK every year. More people die from sepsis than the combined figure for breast cancer and bowel cancer. The GenOMICC study at Roslin Institute has been working to identify better ways to treat the illness, and the DNA samples from NHS patients are invaluable to this research.”

Professor Sir Mark Caulfield, Chief Scientist at Genomics England, said:

“One of the biggest puzzles about COVID-19 is why some patients experience a mild infection, others require intensive care and why for some, it is fatal. Understanding why this is will help us treat people more effectively and protect the most vulnerable. As a result of the GenOMICC COVID-19 study, we are much closer to solving that puzzle. We have also been able to identify potential treatments for COVID after the discovery of five genes associated with the most severe form of the disease.

“The progress we’ve made to date has been down to the thousands of people who had to go to intensive care with COVID-19 and agreed to donate their DNA and health records, as well as their families and hundreds of NHS staff.  This vital work would also not be possible without the generous support of Sepsis Research FEAT. Our huge thanks go to all of them.”

Dr Kenneth Baillie, who leads the team at the Roslin Institute, commented:

“Our ability to deliver world-leading research during the pandemic is a direct consequence of the funding support for GenOMICC from Sepsis Research FEAT, along with the help of NHS staff and patients in collecting samples. Because we were already established across the UK before the COVID outbreak, we were able to extend recruitment to include COVID cases. GenOMICC is now the single best-recruiting consented research study in the history of UK critical care medicine.”


Join our FREE mailing list and receive our Weekly Digest bulletin and other updates direct to your inbox.

Related News

Skip to content